NCT07253272

A PET Study of ENX-104 in Healthy Volunteers

An Open-label Positron Emission Tomography (PET) Study to Demonstrate Safety, Tolerability, Receptor Occupancy, and Pharmacokinetics After a Single Oral Dose Administration of ENX-104 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Engrail Therapeutics INC · Industry
• Sex: All
• Age: 23 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The study is designed to evaluate the D2/D3 receptor occupancy (RO), safety, tolerability, and pharmacokinetics (PK) of ENX-104 in healthy volunteers.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ENX-104	Oral solution

Timeline

• Start date: 2025-02-24
• Primary completion: 2025-09-02
• Completion: 2025-09-02
• First posted: 2025-11-28
• Last updated: 2025-11-28

Locations

1 site across 1 country: United Kingdom